Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 199

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 199
---
 and the absence of any formal SEC inquiries or investigations pending or threatened, in 
 each case regarding any accounting practices of Enfusion;                                                                                                                                                                                             |

| • |     | Enfusion’s financial statements; |

| • |     | Enfusion’s disclosure controls and procedures; |

| • |     | Enfusion’s internal accounting controls and procedures; |

| • |     | the absence of specified undisclosed liabilities; |

| • |     | legal proceedings; |

| • |     | Enfusion’s and its subsidiaries’ possession of necessary governmental authorizations; |

| • |     | the existence, validity and enforceability of specified categories of Enfusion’s and its subsidiaries’                                                                             
 material contracts, and any notices with respect to violation, termination, material decrease in the amount of business or intent not to renew those material contracts therefrom; |

| • |     | tax matters, including the absence of any actions by, or knowledge of any facts or circumstances by, Enfusion or                                                                           
 its subsidiaries that could reasonably be expected to prevent the Corporate Mergers, taken together, from qualifying as a reorganization within the meaning of Section 368(a) of the Code; |

| • |     | employee benefit plans; |

| • |     | labor and employment matters; |

| • |     | insurance matters; |

| • |     | environmental matters; |

| • |     | trademarks, patents, copyrights and other intellectual property matters; |

| • |     | information technology systems; |

| • |     | artificial intelligence systems; |

| • |     | real property leased or subleased by Enfusion and its subsidiaries; |

| • |     | data security and privacy matters; |

| • |     | payment of fees to brokers in connection with the Merger Agreement; |

| • |     | the rendering of Goldman Sachs’ fairness opinion to the Enfusion Board; |

| • |     | the inapplicability of anti-takeover statutes to the Merger Agreement, the Support Agreements, the Transactions 
 and the transactions contemplated thereby; and                                                                  |

| • |     | Enfusion and its subsidiaries’ absence of ownership of any shares of capital stock of Clearwater. |

In the Merger Agreement, the Buyer Parties made customary representations and warranties to Enfusion that are subject, in some cases, to specified exceptions and qualifications contained in the Merger Agreement. These representations and warranties relate to, among other things:

| • |     | due organization, good standing and authority and qualification to conduct business